AAAAAA
Results:
1-11
|
Results: 11
Authors:
Di Leo, A
Larsimont, D
Gancberg, D
Jarvinen, T
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Ries, F
Gobert, P
Closon-Dejardin, MT
Dolci, S
Rouas, G
Paesmans, M
Lobelle, JP
Isola, J
Piccart, MJ
Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089
Authors:
Cardoso, F
Di Leo, A
Larsimont, D
Gancberg, D
Rouas, G
Dolci, S
Ferreira, F
Paesmans, M
Piccart, M
Citation: F. Cardoso et al., Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes, ANN ONCOL, 12(5), 2001, pp. 615-620
Authors:
Piccart, MJ
Di Leo, A
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Tagnon, A
Ries, F
Gobert, P
Finet, C
Closon-Dejardin, MT
Dufrane, JP
Kerger, J
Liebens, F
Beauvois, S
Bartholomeus, S
Dolci, S
Lobelle, JP
Paesmans, M
Nogaret, JM
Citation: Mj. Piccart et al., Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J CL ONCOL, 19(12), 2001, pp. 3103-3110
Authors:
Cardoso, F
Ferreira, AF
Crown, J
Dolci, S
Paesmans, M
Riva, A
Di Leo, A
Piccart, MJ
Citation: F. Cardoso et al., Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicinin the adjuvant treatment of node positive breast cancer: Results of a feasibility study, ANTICANC R, 21(1B), 2001, pp. 789-795
Authors:
Giannantoni, A
Di Stasi, SM
Scivoletto, G
Virgili, G
Dolci, S
Porena, M
Citation: A. Giannantoni et al., Intermittent catheterization with a prelubricated catheter in spinal cord injured patients: A prospective randomized crossover study, J UROL, 166(1), 2001, pp. 130-133
Authors:
Dolci, S
Pellegrini, M
Di Agostino, S
Geremia, R
Rossi, P
Citation: S. Dolci et al., Signaling through extracellular signal-regulated kinase is required for spermatogonial proliferative response to stem cell factor, J BIOL CHEM, 276(43), 2001, pp. 40225-40233
Authors:
Viglietto, G
Dolci, S
Bruni, P
Baldassarre, G
Chiariotti, L
Melillo, RM
Salvatore, G
Chiappetta, G
Sferratore, F
Fusco, A
Santoro, M
Citation: G. Viglietto et al., Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine growth factors stimulating DNA synthesis of Ret-expressing spermatogonia, INT J ONCOL, 16(4), 2000, pp. 689-694
Authors:
Di Leo, A
Crown, J
Nogaret, JM
Duffy, K
Bartholomeus, S
Dolci, S
Rowan, S
O'Higgins, N
Paesmans, M
Larsimont, D
Riva, A
Piccart, MJ
Citation: A. Di Leo et al., A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer, ANN ONCOL, 11(2), 2000, pp. 169-175
Authors:
Rossi, P
Sette, C
Dolci, S
Geremia, R
Citation: P. Rossi et al., Role of c-kit in mammalian spermatogenesis, J ENDOC INV, 23(9), 2000, pp. 609-615
Authors:
Sette, C
Dolci, S
Geremia, R
Rossi, P
Citation: C. Sette et al., The role of stem cell factor and of alternative c-kit gene products in theestablishment, maintenance and function of germ cells, INT J DEV B, 44(6), 2000, pp. 599-608
Authors:
Di Stasi, SM
Giannantoni, A
Massoud, R
Dolci, S
Navarra, P
Vespasiani, G
Stephen, RL
Citation: Sm. Di Stasi et al., Electromotive versus passive diffusion of mitomycin C into human bladder wall: Concentration-depth profiles studies, CANCER RES, 59(19), 1999, pp. 4912-4918
Risultati:
1-11
|